Skip to main content

Table 4 Surface marker expression of DC 6 days after culture from PBMCs

From: A phase I clinical study of immunotherapy for advanced colorectal cancers using carcinoembryonic antigen-pulsed dendritic cells mixed with tetanus toxoid and subsequent IL-2 treatment

Marker

HLA-DR

CD86

CD40

Patient

1

93.39a

96.47

98.22

2

95.4

85.36

99.41

3

83.14

94.17

95.51

4

95.2

94.98

96.64

5

97.92

93.64

98.96

6

95.98

87.72

94.75

7

84.4

93.08

97.24

8

86.25

95.35

99.18

9

94.03

96.22

94.54

10

90.67

93.29

97.71

11

89.52

97.43

98.25

12

95.9

93.76

95.97

Mean ± SD

91.8 ± 4.96

93.5 ± 5.34

97.2 ± 1.71

  1. aResults were expressed as the percentage of cells stained positive for a given mAb
Back to article page

Journal of Biomedical Science

ISSN: 1423-0127